Does Conjugated Estrogensbazedoxifene Interact with Carbamazepine?
CDI records a moderate classification for Conjugated Estrogensbazedoxifene and Carbamazepine. The stored summary is: CYP3A4 and UGT inducer may reduce estrogen and bazedoxifene concentrations, decreasing therapeutic effects and increasing endometrial hyperplasia risk. The mechanism involves cyp3a4 and ugt induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Conjugated Estrogensbazedoxifene Class
- Estrogen
- Carbamazepine Class
- Mood Stabilizer
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 and UGT induction
What To Tell Your Doctor or Pharmacist
If you are taking Conjugated Estrogensbazedoxifene and your doctor is considering prescribing Carbamazepine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider